EMA Authorised: Eyluxvi (aflibercept) — Biolitec pharma Limited Zweigniederlassung Jena

View source ↗

Summary

EMA authorised Eyluxvi (aflibercept) from Biolitec pharma Limited Zweigniederlassung Jena for treatment of wet age-related macular degeneration, macular edema, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Macular Edema
• Retinal Vein Occlusion
• Wet Age-related Macular Degeneration

Drugs mentioned

• Eyluxvi (aflibercept)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion. MAH: Biolitec pharma Limited Zweigniederlassung Jena. Decision date: 15/09/2025